Progenity Gets $125M in Financing to Speed Development of IBD Diagnostics, Therapeutics Platform

Progenity Gets $125M in Financing to Speed Development of IBD Diagnostics, Therapeutics Platform
Progenity recently closed a $125 million financing round to accelerate development of its gastrointestinal (GI) platform for inflammatory bowel disease (IBD), including precision molecular diagnostic tools, precision therapeutics, microbiome analytics and consumer health nutrition. The financing was led by a fund managed by a long-time investor, Athyrium Capital Management. “Proceeds will be used to enhance our

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *